Barr Will Host an Earnings Conference Call on August 7, 2008 to Discuss the Results for the Second Quarter of Calendar 2008
The Conference Call will also be Webcast live on the Internet. Investorsand other interested parties may access the live webcast through the Investorssection, under Calendar of Events, on Barr's website at www.BarrLabs.com.
Log on at least 15 minutes before the call begins to register and downloador install any necessary audio software.
About Barr Pharmaceuticals, Inc.
Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical companythat operates in more than 30 countries worldwide and is engaged in thedevelopment, manufacture and marketing of generic and proprietarypharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. Aholding company, Barr operates through its principal subsidiaries: BarrLaboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and itssubsidiaries. The Barr Group of companies markets more than 120 generic and 27proprietary products in the U.S. and approximately 1,025 products globallyoutside of the U.S. For more information, visit www.barrlabs.com.
Except for the historical information contained herein, the statementsmade in this press release constitute forward-looking statements within themeaning of Section 27A of the Securities Act of 1933 and Section 21E of theSecurities Exchange Act of 1934. Forward-looking statements can be identifiedby their use of words such as "expects," "plans," "projects," "will," "may,""anticipates," "believes," "should," "intends," "estimates" and other words ofsimilar meaning. Because such statements inherently involve risks anduncertainties that cannot be predicted or quantified, actual results maydiffer materially from those expressed or implied by such forward-lookingstatements depending upon a number of factors affecting the Company'sbusiness. These factors include, among others: the difficulty in predictingthe timing and outcome of legal proceedings, including patent-related matterssuch as patent challenge settlements and patent infringement cases; theoutcome of litigation arising from challenging the validity ornon-infringement of patents covering our products; the difficulty ofpredicting the timing of FDA approvals; court and FDA decisions on exclusivityperiods; the ability of competitors to extend exclusivity periods for theirproducts; our ability to complete product development activities in thetimeframes and for the costs we expect; market and customer acceptance anddemand for our pharmaceutical products; our dependence on revenues fromsignificant customers; reimbursement policies of third party payors; ourdependence on revenues from significant products; the use of estimates in thepreparation of our financial statements and our forecasts; the impact ofcompetitive products and pricing on products, including the launch ofauthorized generics; the ability to launch new products in the timeframes weexpect; the availability of raw materials; the availability of any product wepurchase and sell as a distributor; the regulatory environment in the marketswhere we operate; our exposure to product liability and other lawsuits andcontingencies; the increasing cost of insurance and the availability ofproduct liability insurance coverage; our timely and successful completion ofstrategic initiatives, incl
You May Also Like